Sökning: "BRAF-inhibitor"
Visar resultat 1 - 5 av 7 avhandlingar innehållade ordet BRAF-inhibitor.
1. Experimental treatment of patients with disseminated malignant melanoma
Sammanfattning : Malignant melanoma (MM) is the deadliest skin cancer with an ever-increasing incidence. New treatments have improved the prognosis for patients with advanced MM. Still, most patients do not respond, and the side effects can be severe, underlining the need for better therapies. LÄS MER
2. Regulation of WNT5A Expression in Malignant Melanoma: Role in Tumor Progression
Sammanfattning : .... LÄS MER
3. Unravelling molecular mechanisms underlying therapy resistance in cutaneous melanoma
Sammanfattning : For many years the standard treatment of advanced metastatic melanoma with chemotherapeutic agents, including temozolomide (TMZ) and dacarbazine (DTIC), has been unsuccessful. The paradigm shift in melanoma treatment occurred with the identification of mutations in the BRAF gene that leads to a constitutively active BRAF V600E protein. LÄS MER
4. Clinical aspects of molecular profiles in metastatic malignant melanoma
Sammanfattning : Malignant melanoma is a heterogeneous, malignant neoplastic disease, most often originating in the skin. Melanoma is characterized by a high mutational load and has a vastly variable prognosis, depending on disease stage. LÄS MER
5. Hitting the right targets : a study of molecular mediators of sensitivity to novel potential targeted therapies in cutaneous malignant melanoma
Sammanfattning : Cutaneous malignant melanoma (CMM) is the deadliest form of skin cancer with a 5-year overall survival (OS) rate of less than 10% among patients diagnosed with disseminated disease. During the past decade the emergence and use of novel targeted therapy and immunotherapy has significantly increased the 5-year OS rate (34%). LÄS MER